Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the second quarter ended June 30, 2021.
- Completed enrollment of the Phase 3 LAVENDER study evaluating trofinetide for the treatment of Rett syndrome, with top-line results expected in the fourth quarter of 2021.
- Initiated a Phase 2 study of ACP-044 for pain associated with osteoarthritis in the second quarter of 2021.
- Acadia management will review its second quarter financial results and operations via conference call and webcast today at 4:30 p.m. Eastern Time.